Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence

BACKGROUND: Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) has limited progression‐free survival (PFS) benefit. We hypothesized that adding cetuximab to methotrexate improves PFS. METHODS: In the phase‐Ib‐study, patients with R/M SCCHN received met...

Descripción completa

Detalles Bibliográficos
Autores principales: Ham, Janneke C., van Meerten, Esther, Fiets, W. Edward, Beerepoot, Laurens V., Jeurissen, Frank J. F., Slingerland, Marije, Jonker, Marianne A., Husson, Olga, van der Graaf, Winette T. A., van Herpen, Carla M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216894/
https://www.ncbi.nlm.nih.gov/pubmed/31903657
http://dx.doi.org/10.1002/hed.26053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216894/
https://www.ncbi.nlm.nih.gov/pubmed/31903657
http://dx.doi.org/10.1002/hed.26053

Ejemplares similares